# Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes

> **NCT01159600** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 1504 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Placebo identical to BI 10773 high dose
- **DRUG:** Placebo identical to BI 10773 low dose
- **DRUG:** BI 10773
- **DRUG:** BI 10773
- **DRUG:** Placebo identical to BI 10773 low dose
- **DRUG:** BI 10773
- **DRUG:** Placebo identical to BI 10773 high dose

## Key facts

- **NCT ID:** NCT01159600
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2012-02
- **Final completion:** —
- **Target enrollment:** 1504 (ACTUAL)
- **Last updated:** 2014-06-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01159600

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01159600, "Efficacy and Safety Study With Empagliflozin (BI 10773) vs. Placebo as add-on to Metformin or Metformin Plus Sulfonylurea Over 24 Weeks in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01159600. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*